About Us  |  Contact Us  |  Feedback  |  Portfolio  |  Press  |  Advertise  |  Careers  |  Sitemap 
Medindia
   
   Google Search   Advanced Search
Web Medindia   
Health News RSSHealth news
Disease News RSSDisease News
SubscribeSubscribe
Login
Password
Forgot Password   New User
Medindia On MobileMedindia On Mobile Buy Health ProductsBuy Health Products
Medindia » Latest Health News » Several Vaccine Trials Affected by Halt of Merck's HIV Vaccine Trial
Latest Headlines
'Mouse' Turns 40 Today! (6 hrs ago)
Pregnant Women With Gestational Diabetes Mellitus on the Rise (6 hrs ago)
Chemical In Paint Could Promote Obesity: Study (7 hrs ago)
'Nayana' - A Unique Mobile Eye Care Initiative For Diabetics (7 hrs ago)
New Method That Helps Reduce Breast-lesion Biopsies Developed (7 hrs ago)
'Doctor At Your Doorstep' Becomes A Reality In Chunampet (7 hrs ago)
Antibiotics Blamed For Drug-induced Liver Injury (7 hrs ago)
All Latest News
News - Quick Links
News Central
Latest Health News
News Category
Popular News
Health News and Press Release
Special Reports
Health Watch
Health In Focus
Breaking Health News
Celebrating Life
Medindia - Exclusive
India Special
Lifestyle and Wellness
Popular News Topics
Drug News    Subscribe
Posted online: Sunday, November 18, 2007 at 11:46:19 AM
Font Size

Several Vaccine Trials Affected by Halt of Merck's HIV Vaccine Trial

Several vaccine trials are being postponed or modified following the halt of Merck's experimental HIV vaccine trial. Merck in September announced that it had ended the Phase II trial, which began in late 2004 and involved HIV-negative volunteers, after the experimental vaccine failed to prevent HIV infection in participants or prove effective in delaying the progression of the virus to AIDS.



New data recently suggested that the vaccine was ineffective among some trial participants with a pre-existing immunity to a common cold virus and that the vaccine might have increased their susceptibility to HIV infection. The Merck vaccine was made from a weakened version of a common cold virus that served as a mode for providing three synthetically produced genes from HIV, known as gag, pol and nef.

After several days of discussions at an HIV Vaccine Trials Network conference last week in Seattle of Merck's trial, leaders of the trial on Monday decided to notify all of the trial's 3,000 participants whether they were given the vaccine or a placebo.

Other trials have been affected by Merck's trial because the experimental vaccines have a similar structure to Merck's vaccine. Trial participants now must be warned about the potential risks highlighted in the Merck trail if they participate in experiments that use a cold-virus carrier similar to Merck's product, Anthony Fauci, director of the National Institute of Allergy and Infectious Disease, said.
Page 1 Page 1 | 2  Next

 Related Links
Medindia on AIDS/HIV Treatment
Human Immunodeficiency Virus attacks the CD4 immune cells, which are the immune system cells. CD4 cells trigger the immune system to create antibodies in order to fight off infection. As HIV destroys the CD4 cells, the function of immune system is suppressed and the affected person is not able to defend infection.

Read More...

For More Information
AIDS/HIV- Lab Tests & FAQs
Merck's Vaccine Trial Halt Made Experts to Focus on Other HIV Prevention Tactics
 
 Share this News with:
Digg It
Digg
Del.icio.us
Del.icio.us
Stumbleupon
StumbleUpon
Google
Google
Windows Live
Windows Live
NewsVine
Newsvine
Reddit
Reddit
Post Your Comments
Be the first to comment
* Name
   (For display)
* Email
* Your Email address will not be displayed on the site or used to send unsolicited e-mails.
* Comment
* Your comment can be maximum of 2500 characters
           

Please keep your comments short, relevant and to the point
Do not use objectionable language
Do not provide personal information in the comments
Drug Related News
Antibiotics Blamed For Drug-induced Liver Injury
Nifedipine Shows No Benefit in Preventing Pre-mature Birth
Dutch Court Rejects Bid Against 'Magic Mushroom' Ban
Experimental Drug Shows Promise Against Latent TB Bacteria
New Class of Cholesterol-lowering Drugs Developed
Read More

Resources HIV - Complete Medindia Resources
 News Archive

 Search by Keyword


Web Medindia  Advanced Search
Feedback
Last Updated - - Designed & Content Managed by Medindia Health Network Pvt Ltd. Hosted & Technical Support by FrontPoint Systems
DisclaimerThe contents of this site are for informational purposes only. Always seek the advice of a qualified physician for any doubts.
To Read full Disclaimer Click Here!
Best viewed with resolution 1024x768 px.
Advertise with us |  Medindia Copyright |  Privacy Policy |  © All Rights Reserved 1997 - 2008